Inhaled nitric oxide developer Beyond Air announced that pulmonologist Andrew Colin has been appointed as the company’s Chief Medical Officer, effective December 1, 2021. Colin, who was most recently Chief of the Division of Pediatric Pulmonology at the University of Miami’s Miller School of Medicine and Director of the university’s Cystic Fibrosis Center, has extensive experience researching inhaled drugs, including the use of DNase and inhaled amikacin in CF patients.
Beyond Air is developing its LungFit inhaled NO systems for both hospital and home use for the treatment of respiratory conditions such as COVID-19 pneumonia, bronchiolitis, and NTM lung infections. The LungFit system generates NO for inhalation from ambient air and does not require the use of a gas cylinder.
Beyond Air Chairman and CEO Steve Lisi said, “I am delighted and honored to welcome Dr. Colin to the Beyond Air family. Dr. Colin’s contributions as a longtime member of our scientific advisory board have already been instrumental to the progress of our ongoing clinical programs, specifically in bronchiolitis and NTM. I am excited to see the growth of our clinical programs under his leadership.”
Colin responded, “I am thrilled to join Beyond Air at such an exciting time in the company’s history. Throughout my time on Beyond Air’s scientific advisory board I have developed a productive partnership with the executive team and have become very well versed on the company’s ongoing clinical programs, as well as strategic plans. I am excited to accelerate these activities and help lead the late-stage development efforts and potential commercialization of both LungFit PRO and LungFit GO systems in acute viral respiratory infections, NTM, and other future indications.”
Read the Beyond Air press release.
